Treatment and tumor response. The patients are listed in the same sequence in Tables 1, 3, and 4. The vertical colored bars indicate vaccine components. All patients received HLA-A2 binding peptides derived from influenza matrix protein and from Melan-A [either natural (nat) or analog (ana) peptide]. Peptides were given without adjuvant (group I), mixed with AS02B (groups II and IVa), or mixed with IFA (groups III and IVb). For group IV, vaccines were accompanied by 7-d treatments with low dose IL-2 s.c. Abbreviations: PR, partial response; MR, mixed response (regressing metastasis concomitant with progressing metastases); NMD, no measurable disease; PD, progressive disease; SD, stable disease.